Over the last 120 years, the extensive advances in medical imaging allowed enhanced diagnosis and therapy of many diseases and thereby improved the quality of life of many patient generations. From the beginning, all technical solutions and imaging procedures were combined with dedicated pharmaceutical developments of contrast media, to further enhance the visualization of morphology and physiology. This symbiosis of imaging hardware and contrast media development was of high importance for the development of modern clinical radiology. Today, all available clinically approved contrast media fulfill the highest requirements for clinical safety and efficacy. All new concepts to increase the efficacy of contrast media have also to consider the high clinical safety standards and cost of goods of current marketed contrast media. Nevertheless, diagnostic imaging will contribute significantly to the progresses in medicine, and new contrast media developments are mandatory to address the medical needs of the future.
From the *MR and CT Contrast Media Research, Bayer Healthcare AG; †Department of Physical and Theoretical Chemistry, Free University; ‡Department of Radiology, Charite-Universitätsmedizin Berlin, Campus Benjamin Franklin; and §Clinical Project Management General Medicine, Bayer Healthcare AG, Berlin, Germany.
Received for publication April 17, 2015; and accepted for publication, after revision, May 22, 2015.
Conflicts of interest and sources of funding: T.S, G.J., J.L., M.A.S. and H.P. are employees of Bayer Healthcare, R.L. is a retired employee of Bayer Healthcare.
Correspondence to: Hubertus Pietsch, PhD, MR and CT Contrast Media Research, Bayer Pharma AG, Müllerstrasse 178, 13353 Berlin, Germany. E-mail: email@example.com.